Galectin Therapeutics Inc. [NASDAQ: GALT] gained 13.01% on the last trading session, reaching $3.91 price per share at the time. The company report on April 19, 2021 that World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin.
Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. Uihlein.
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced it has engaged Dr. Ben Carson, Sr., a world-renowned neurosurgeon and the 17th Secretary of the U.S. Department of Housing and Urban Development, as a special consultant to assist with development of the Company’s galectin-3 inhibitor, belapectin, as a treatment for NASH cirrhosis and in combination with immunotherapy for the treatment of cancers.
Galectin Therapeutics Inc. represents 57.08 million in outstanding shares, while the company has a total market value of $197.81 million with the latest information. GALT stock price has been found in the range of $3.25 to $4.19.
If compared to the average trading volume of 2.15M shares, GALT reached a trading volume of 5084131 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Galectin Therapeutics Inc. [GALT]:
H.C. Wainwright have made an estimate for Galectin Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 13, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on February 13, 2019, representing the official price target for Galectin Therapeutics Inc. stock. Previously, the target price had yet another raise from $6 to $10, while H.C. Wainwright kept a Buy rating on GALT stock. On November 28, 2017, analysts increased their price target for GALT shares from 3.50 to 6.
The Average True Range (ATR) for Galectin Therapeutics Inc. is set at 0.41 The Price to Book ratio for the last quarter was 10.29, with the Price to Cash per share for the same quarter was set at 0.54.
Trading performance analysis for GALT stock
Galectin Therapeutics Inc. [GALT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 78.54. With this latest performance, GALT shares gained by 90.73% in over the last four-week period, additionally plugging by 48.11% over the last 6 months – not to mention a rise of 118.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GALT stock in for the last two-week period is set at 73.95, with the RSI for the last a single of trading hit 79.17, and the three-weeks RSI is set at 70.44 for Galectin Therapeutics Inc. [GALT]. The present Moving Average for the last 50 days of trading for this stock 2.38, while it was recorded at 3.16 for the last single week of trading, and 2.55 for the last 200 days.
Galectin Therapeutics Inc. [GALT]: A deeper dive into fundamental analysis
Return on Total Capital for GALT is now -67.05, given the latest momentum, and Return on Invested Capital for the company is -67.19. Return on Equity for this stock declined to -67.25, with Return on Assets sitting at -60.12. When it comes to the capital structure of this company, Galectin Therapeutics Inc. [GALT] has a Total Debt to Total Equity ratio set at 0.21. Additionally, GALT Total Debt to Total Capital is recorded at 0.21, with Total Debt to Total Assets ending up at 0.18. Long-Term Debt to Equity for the company is recorded at 0.04, with the Long-Term Debt to Total Capital now at 0.03.
Reflecting on the efficiency of the workforce at the company, Galectin Therapeutics Inc. [GALT] managed to generate an average of -$3,910,833 per employee.Galectin Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.50 and a Current Ratio set at 5.50.
Galectin Therapeutics Inc. [GALT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Galectin Therapeutics Inc. posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GALT.
An analysis of insider ownership at Galectin Therapeutics Inc. [GALT]
There are presently around $40 million, or 17.80% of GALT stock, in the hands of institutional investors. The top three institutional holders of GALT stocks are: BLACKROCK INC. with ownership of 2,598,089, which is approximately 3.794% of the company’s market cap and around 11.60% of the total institutional ownership; VANGUARD GROUP INC, holding 1,880,527 shares of the stock with an approximate value of $7.35 million in GALT stocks shares; and ADVISOR GROUP HOLDINGS, INC., currently with $4.29 million in GALT stock with ownership of nearly 5.807% of the company’s market capitalization.
Positions in Galectin Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 33 institutional holders increased their position in Galectin Therapeutics Inc. [NASDAQ:GALT] by around 686,385 shares. Additionally, 22 investors decreased positions by around 406,857 shares, while 24 investors held positions by with 9,203,527 shares. The mentioned changes placed institutional holdings at 10,296,769 shares, according to the latest SEC report filing. GALT stock had 12 new institutional investments in for a total of 245,606 shares, while 3 institutional investors sold positions of 70,459 shares during the same period.